TY  - JOUR
T1  - Leukotriene Receptor Antagonist in Treating Allergic Rhinitis; Literature Review
A1  - Tamim Khalid Alzughaibi
A1  - Raghad Fuad Alhejaili
A1  - Ahmad Zaher Ali
A1  - Abdulrahman Jaber Alfaifi
A1  - Husam Mohammed Almaramhi
A1  - Abdulrahman Fahad Alqifari
A1  - Abdullah Shref Alwthainani
A1  - Riam Saleh Alkhamis
A1  - Nasser Tareq Aldosari
A1  - Bader Ahmad Alshammari
JF  - Journal of Biochemical Technology
JO  - J Biochem Technol
SN  - 0974-2328
Y1  - 2021
VL  - 12
IS  - 4
DO  - 10.51847/hg79JzKyou
SP  - 99
EP  - 103
N2  - A type 1 hypersensitivity disorder is Allergic rhinitis that affects the nasal mucosa and is described by frequent attacks of rhinorrhea and sneezing, nasal pruritus, and nasal congestion. It is the most regular disease stated in the ENT clinic and is generally controlled by nasal corticosteroids, vasoconstrictors, oral antihistamines, oral leukotriene receptor antagonists, or a medley of these agents. This study aimed to study the literature on the disease and to evaluate the effectiveness and safeness of leukotriene receptor antagonists compared with other therapeutic agents. We checked the PubMed database and searched for related articles toward the issue. We used the following Mesh words: Leukotriene receptor antagonists, rhinitis, allergic rhinitis, montelukast. The leukotriene (montelukast) receptor antagonist appears to play a restorative role in the treatment of patients with asthma and allergic rhinitis. However, compared with other agents, most current trials reported that montelukast provides greater effect in allergic rhinitis patients than placebo, especially nighttime symptoms, equal effect to antihistamine, and inferior to nasal corticosteroids. Additionally, montelukast, when combined with other agents, seems to provide a greater beneficial effect than monotherapy. 
UR  - https://jbiochemtech.com/article/leukotriene-receptor-antagonist-in-treating-allergic-rhinitis-literature-review-2haw6jbg7kaw6hy
ER  -